Pivotal Phase 3 oPTimize trial design builds on positive Phase 2 Avail™ results and durable

one-year clinical benefit

Global registrational trial to enroll approximately 160 adults with HP to support once-weekly

canvuparatide’s potential as a best-in-class PTH replacement therapy

CARMEL, Ind., and BURLINGTON, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that the first patient has been dosed in its pivotal Phase 3 oPTimize clinical trial evaluating once-weekly canvuparatide for the treatment of chronic hypoparathyroidism (HP).

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.